Patrick Baeuerle
Excutive Partner @ MPM Capital
Cambridge, United States
Patrick Baeuerle is a Series A investor at MPM Capital in Cambridge focused on Medical and Health Care. Patrick A. Baeuerle is the Executive Partner of MPM Capital. He previously worked at Amgen Research as a Vice President of Research and General Manager. Patrick A. Baeuerle attended the University of Konstanz and LMU Munich.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Patrick Baeuerle invests in
Stages Patrick Baeuerle invests in
Countries Patrick Baeuerle invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Health Care 1 (50%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to expressdefined TCR alpha/beta chains.TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. | $125M / Series B / Mar 21, 2018 | ||
| TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to expressdefined TCR alpha/beta chains.TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. | $44.5M / Series A / Dec 08, 2016 |
Co-Investors
About MPM Capital
MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.
MPM Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Hicklin
Managing Director
|
|||
David P. Ryan
Medical and Scientific Advisor
|
|||
Detlev Biniszkiewicz
Executive Partner
|
|||
|
Patrick Baeuerle
Excutive Partner
|
|||
Uciane Scarlett
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Patrick Baeuerle invest in?
Patrick Baeuerle invests primarily in Medical, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Patrick Baeuerle?
Public channels for Patrick Baeuerle include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Patrick Baeuerle last invest?
The most recent investment recorded for Patrick Baeuerle closed in Mar 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
